Monsenso digital health solution is HIPAA compliant

Monsenso digital health solution is HIPAA compliant

Monsenso A/S, a technology leader in digital health solutions for mental health is HIPAA compliant. The Monsenso digital health solution that connects individuals and clinicians to provide optimal care adheres to the highest standards for data security and privacy. In addition to being HIPAA compliant, Monsenso holds ISO 13485 and ISO 27001 certifications, Cyber Essentials certification, a TGA certification and class 1 CE mark.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) was enacted by the U.S. Department of Health and Human Services (HHS) and is a federal law that mandates the creation of national standards to protect patients’ sensitive health information from disclosure without their consent or knowledge.

To read more about our data protection, download our Data management & Security fact sheet.

About Monsenso

Monsenso is an innovative technology company offering a digital health solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com.

For additional information contact:

Bettina van Wylich-Muxoll
Chief Marketing Officer
Monsenso
+45 22 70 47 24
marketing@monsenso.com

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Sciences 
Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Monsenso signs contract with the Norwegian University of Science & Technology

Monsenso signs contract with the Norwegian University of Science & Technology

Monsenso has signed a contract with the Norwegian University of Science & Technology to use Monsenso’s digital health solution to collect sensor data in a research project aiming at improving relapse prevention with substance use disorders.

The research study aims to improve the prediction of relapse using mobile sensing to identify a digital phenotype approach to relapse prevention. The research project is led by Anders Lauvsnes, Department of Mental Health, Faculty of Medicine and Health Sciences, at the Norwegian University of Science & Technology and covers up to 100 research participants with substance use disorders.

Mobile sensing, the use of passive data generated by personal electronic devices such as smartphones and wearables to measure human functioning, has generated considerable research interest over the past years. Particularly in the field of mental health, where the collection of continuous and objective data can lead to clinically useful biomarkers to support the prevention, early intervention, and treatment of a variety of conditions, including addiction.

“Addiction and substance use disorders are major health challenges worldwide, and relapse is a core component of addictive disorders. The dynamics surrounding relapse, and particularly the immediate period leading up to it, are only partially understood, due in large part to the difficulty of collecting reliable and sufficient data from this narrow period,” says Anders Lauvsnes. “Mobile sensing offers the opportunity to identify predictive patterns of relapse by accurately mapping behaviour. Together with data on symptoms worsening, it can help us identify a digital phenotype for relapse prevention”.

The Monsenso digital solution will be used to remotely monitor study participants, collecting sensor data from mobile phones along with sensor data from wearables (Whitings). After completion of the data collection, the data will be analysed along with neurocognitive measures using machine learning to predict imminent relapse to substance use and describe individual and temporal variability in risk.

“We are very excited to contribute to this project of creating a digital phenotype to help reduce relapse,” said Thomas Lethenborg, CEO of Monsenso. “Mobile sensing does indeed offer a data-driven method to improve condition monitoring for actionable outcomes, such as early signs of relapse, thereby ensuring the right individuals receive the right treatment at the right time”.

About Monsenso digital health solution:
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs two contracts with the Psychiatric Research Unit, Region West Zealand.

Monsenso signs two contracts with the Psychiatric Research Unit, Region West Zealand.

Monsenso signs two contracts with Research Unit for Psychotherapy and Psychopathology, Psychiatry West, Slagelse, Region Zealand Mental Health Services, who will use Monsenso’s digital health solution to remotely monitor patients with depression and schizotypal mental illness, respectively.

The first project, Development of an Intervention for Persistent Not on Track: DIP NOT, led by Jasmin Rejaye Gryesten, aims to identify non-responders to depression treatment, with the ultimate goal of increasing the number of remitted patients after CBT in the Danish MHS by developing a set of new person-centered add-on interventions to group CBT, to be used in case of observed lack of progress or deterioration.

The second project Phenomenologically informed PsychoTherapy for patients with Schizotypal Personality Disorder (PPT -SPD), is led by Kåre Donskov Nielsen and aims to develop and test new forms of phenomenological therapy that can help people with schizotypal mental illness.

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Using the Monsenso digital self-monitoring tool for borderline treatment

Using the Monsenso digital self-monitoring tool for borderline treatment

The Monsenso digital self-monitoring tool was tested in a pilot study by individuals with Borderline Personality Disorder in a Public-Private Innovation Partnership between The Zealand Healthcare Region and Monsenso.

The Zealand Healthcare Region, which provides medical services to more than 820,000 citizens, was looking for a smartphone-based application to replace the existing paper-based self-assessments and clinical questionnaires. The application was used in a pilot study to support the treatment of 30 patients with Borderline Personality Disorder receiving Dialectical Behavioural Therapy (DBT) and it ran from January 2016 to January 2017.

 Objectives

The main goals of the pilot study were to identify and track the triggers and early warning signs of individuals with BPD using the digital self-monitoring tool, and to evaluate the project from a Mini Medical Technology Assessment (MTV) perspective, in relation to performance, future impact on patient outcomes and financial implications.

Challenges

  • To provide patients and healthcare providers with an effective digital self-monitoring tool that is able to identify and track triggers and early warning signs
  • To optimise the treatment of BPD and to reinforce the recovery process by improving patients’ access to information about their illness
  • To configure, further develop, and install the Monsenso digital self-monitoring tool so that it can be tested in day-to-day operations in the psychiatry unit in Region Zealand

The Monsenso digital self-monitoring tool

The Monsenso mHealth solution is configured to meet the needs and track the symptoms of patients with borderline. It is based on a double-loop treatment model that connects patients and healthcare providers. The Monsenso digital self-monitoring tool gives patients the opportunity to enter and visualise self-reported data and early warning signs. At the same time, the system provides healthcare providers with access to prognosis, statistics, pattern analysis, risk, and tracking of early warning signs. The solution consists of a smartphone application for patients, and a web portal for healthcare providers. The web portal allows care providers to access all the data collected by the patients’ smartphones, and facilitates data analysis. Each clinic has access to an overview of the patients for whom they are responsible. This allows healthcare providers to monitor patients closely in order to quickly identify when the patients’ conditions are changing and document the process patients go through during their treatment.

Results

Since the 30 patients rapidly embraced the app, when the pilot was completed, they had no wish to return to the paper-based self-assessments. Therefore,  The Zealand Healthcare Region chose to extend the agreement with Monsenso for an additional year, even though the project had not been fully evaluated.

The final evaluation, which will be conducted by the Psychiatric Unit of Research of Region Zealand in Slagelse and the Consolidated Unit of Production, Research and Innovation is set to be concluded in early 2017.

The final evaluation includes a round of interviews with patients and staff, who have been testing the Monsenso solution.

Click here to watch a video displaying patient testimonials.

Click on the links below to learn more about Monsenso’s usage in the treatment of Borderline Personality Disorder: